📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial. (2023)

First Author: Hall FC

Attributed to: Blood-brain barrier dysfunction and risk of dementia following blood-stream infections funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s2213-2600(23)00376-4

PubMed Identifier: 37977159

Publication URI: http://europepmc.org/abstract/MED/37977159

Type: Journal Article/Review

Volume: 11

Parent Publication: The Lancet. Respiratory medicine

Issue: 12

ISSN: 2213-2600